Unlocking the potential of antibody–drug conjugates for cancer therapy
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …
treatments, with dozens more in preclinical and clinical development. The primary goal of …
Site-selective modification strategies in antibody–drug conjugates
SJ Walsh, JD Bargh, FM Dannheim… - Chemical Society …, 2021 - pubs.rsc.org
Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …
Antibody–drug conjugates for cancer therapy
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …
Antibody–drug conjugates: The last decade
N Joubert, A Beck, C Dumontet, C Denevault-Sabourin - Pharmaceuticals, 2020 - mdpi.com
An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …
Cleavable linkers in antibody–drug conjugates
JD Bargh, A Isidro-Llobet, JS Parker… - Chemical Society …, 2019 - pubs.rsc.org
Antibody–Drug Conjugates (ADCs) are now established as a major class of therapeutics for
the clinical treatment of cancer. The properties of the linker between the antibody and the …
the clinical treatment of cancer. The properties of the linker between the antibody and the …
[HTML][HTML] Antibody–drug conjugates: recent advances in linker chemistry
Z Su, D Xiao, F Xie, L Liu, Y Wang, S Fan… - … Pharmaceutica Sinica B, 2021 - Elsevier
Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The
antibody–drug conjugate linker molecule determines both the efficacy and the adverse …
antibody–drug conjugate linker molecule determines both the efficacy and the adverse …
Mechanisms of ADC toxicity and strategies to increase ADC tolerability
TD Nguyen, BM Bordeau, JP Balthasar - Cancers, 2023 - mdpi.com
Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …
Advances in the treatment of acute myeloid leukemia: new drugs and new challenges
NJ Short, M Konopleva, TM Kadia, G Borthakur… - Cancer discovery, 2020 - AACR
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …
the past few years, driven largely by translational research into its genomic landscape and …
Potential of antibody–drug conjugates (ADCs) for cancer therapy
The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …
Ligand-targeted drug delivery
M Srinivasarao, PS Low - Chemical reviews, 2017 - ACS Publications
Safety and efficacy constitute the major criteria governing regulatory approval of any new
drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic …
drug. The best method to maximize safety and efficacy is to deliver a proven therapeutic …